Skip to main content

Pediatric Rheum

Antibiotics are not linked to Autoimmune disease in kids The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, https://t.co/46Q0GFZQiw
Dr. John Cush @RheumNow( View Tweet )
Antibiotics are not linked to Autoimmune disease in kids The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, https://t.co/siIDGezw9W
Dr. John Cush @RheumNow( View Tweet )
Study of 90 Still's Dz pts w/ lung disease from AIDA network - mean age 36 yr; 36% male (13% from pediatrics). Lung findings: pleuritis 72%, parenchymal 34%, ARDS 9.5% & pulm HTN 2.3%. Parenchymal involvement assoc w/ sore throat, pericarditis, higher systemic score, but not https://t.co/4YIx2BwADe
Dr. John Cush @RheumNow( View Tweet )

Antibiotics are not linked to Autoimmune disease in kids

EurekAlert!

The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, Republic of Korea, and colleagues suggests that early

Read Article

Sjögren's Graduates (8.22.2025)

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article
ChildCAPTURE & BioCAPTURE registry studies of 117 pediatric & 243 young adult Psoriasis pts on biologics (753.4 Pt-Yrs) shows no sex differences in clinical responses, but shows females have more adverse events than males (both cohorts) https://t.co/5at9vCqwIO https://t.co/ScJkIH9G31
Dr. John Cush @RheumNow( View Tweet )

Cardiovascular Sequelae in Adults After Kawasaki Disease

A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s. 

Read Article

Teaching You How to Think… (8.15.2025)

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and  aphorisms to live by.

Read Article
Study of 94 children w/ Enthesitis-related arthritis (ERA) - 45 Tunisian, 49 Turkish. While similar demographics, Turkish ERA had signif. more heel pain (61% vs 9%), enthesitis (69% v 40%), &biologics (50 vs 9%); but Tunisian ERA had more sacroiliitis (91% v 55%), Axial Dz (98% v https://t.co/AKNEYoO0C6
Dr. John Cush @RheumNow( View Tweet )
Juvenile Idiopathic Arthritis - NEJM Review Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM). https://t.co/ykI9zAUXaF
Dr. John Cush @RheumNow( View Tweet )

Juvenile Idiopathic Arthritis - NEJM Review

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).

JIA is the most common form of inflammatory arthritis in the pediatric

Read Article
Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significant differences across sJIA clinical phenotypes, with dynamic changes linked to treatment response over time ACR Open Rheumatology https://t.co/GU5y70EXiI https://t.co/oCiKd0INuT
ACR_Journals @ACR_Journals( View Tweet )

A New RA Approval (8.1.2025)

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Read Article
Danish childhood vaccination registry study (1997-2020) found among 1,224,176 children w/ vaccination before age 5, w/ aluminum containing vaccines against an DPT, poliovirus, Hib (DTaP-IPV/Hib), PCV, etc found no increased risk of autoimmune dz by 8 yrs of https://t.co/9IR6AmlIT9
Dr. John Cush @RheumNow( View Tweet )
Emapalumab Approved for MAS in Still’s On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with https://t.co/431PQlzBsV
Dr. John Cush @RheumNow( View Tweet )

CKD & Osteoporosis Rx Revisited (7.25.2025)

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
Congrats to Barbara Anne Eberhard, MD, she has been awarded with the James T. Cassidy Award from the American Academy of Pediatrics (AAP). For her dedication to research/leadership in pediatric rheumatology. She is at Northwell Health’s Cohen Children’s Medical Center & Feinstein https://t.co/USGajXCMLD
Dr. John Cush @RheumNow( View Tweet )
40 kids w/ Psoriasis compared to 40 juvenile PsA pts. Those w/ jPsA were more likely to be: - Obese/overweight (80 vs 17.5%) - passive smoking (37.5 vs (25%) - Signif higher ESR and CRP (P < 0.001) - Nail PsO (65 vs 22%) https://t.co/3uBHnxZYC2 https://t.co/rW48EQta2s
Dr. John Cush @RheumNow( View Tweet )

Emapalumab Approved for MAS in Still’s

On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with inadequate response or intolerance to glucocorticoids.

Read Article
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/hp7sFR6kLa
Dr. John Cush @RheumNow( View Tweet )
Metanalysis of Uveitis & JIA - 28 studies, 22,834 JIA pts w/ 3,381dx w/ uveitis - prevalence = 12.7%,, highest in Europeans (14.3%), lowest in Asian (6.5%). Uveitis risk factors included early age JIA onset, ANA-positive, and increased ESR. https://t.co/MxffJKvbik https://t.co/LDz60uwQTM
Dr. John Cush @RheumNow( View Tweet )
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/IDeEvitIrB
Dr. John Cush @RheumNow( View Tweet )
Don't Stop the DMARDS!! Retrospective study of 91 JIA pts (all types; 36% oligo, 27%poly) all Rx w/ cycles of DMARD therapy. Consistently two-thirds relapsed and flared. Only one-third of JIA patients were able to remain off DMARDs. https://t.co/ifqnMKfhAe https://t.co/8JAbpO1IVe
Dr. John Cush @RheumNow( View Tweet )

Hmmm Really? (7.11.2025)

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

Read Article
Referral of 304 suspected autoinflammatory Dz (SAID) to a UK national centre for primarily adult SAID in 2022, 121 (39.5%) were diagnosed with SAID, w/ half of these having monogenic Dz. Median Dx delay was 2 to 6 yrs, worse in late-onset SAID. https://t.co/x8VOFyjuVA https://t.co/3R2HdYUlSg
Dr. John Cush @RheumNow( View Tweet )
×